October 26, 2020

US regulator advises against hydroxychloroquine for COVID outside the hospital

The governmental US Food and Drug Administration (FDA) recommended on Friday not to use hydroxychloroquine and chloroquine as medical treatments in a hospital for COVID-19, due to the risks of its adverse effects.

“While clinical trials are underway to determine the safety and effectiveness of these drugs for COVID-19, there are known side effects for these drugs that should be considered,” the US regulator explained on its website.

“We recommend that healthcare professionals make decisions for individual patients and closely monitor and supervise these patients to help mitigate these risks,” said the agency, which earlier this month approved a plan urgently to distribute millions of doses of those two. drugs used to treat malaria and now used in critically ill COVID-19 patients.

However, at the moment there are not enough studies to support its benefits and some experts have been concerned, since in the absence of conclusive studies, they believe that the side effects of these drugs can pose a danger if their use is extended, especially for people with heart disease or taking medicines that slow the heart rate.

The FDA has decided to influence the risks posed by these treatments for some patients after this week a study funded by the University of Virginia (UVA) concluded that hydroxychloroquine does not report great benefits and has a higher proportion of deaths among the patients to whom it is administered.

“It is important that healthcare workers are aware of the serious, potential, and life-threatening risks to heart rhythm that can occur with these medications and that are specified in the package leaflet,” the FDA warned.

Since March, US President Donald Trump has publicly made a defense of the use of hydroxychloroquine to treat the SARS-CoV-2 coronavirus, despite the lack of conclusive studies.

However, it has gradually ceased in its efforts to advertise its employment against COVID-19, especially since the publication of the work financed by UVA.


Source link